In vitro contracture test and gene typing in diagnosing malignant hyperthermia

被引:0
|
作者
Rüffert, H
Olthoff, D
Deutrich, C
Thamm, B
Froster, U
机构
[1] Univ Leipzig, Bereich Med, Klin & Poliklin Anasthesiol & Intens Therapie, D-04103 Leipzig, Germany
[2] Univ Leipzig, Inst Humangenet, Leipzig, Germany
来源
ANAESTHESIST | 2000年 / 49卷 / 02期
关键词
malignant hyperthermia; MH-diagnosis; genotyping; in vitro contracture test;
D O I
10.1007/s001010050017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Malignant hyperthermia (MH) is an autosomal dominantly inherited disorder,triggered in susceptible individuals by inhalation anesthetics and depolarizing muscle relaxants such as succinylcholine. Because of its high sensitivity (97-99%) and specificity (93,6%) as well as the genetic heterogeneity of MH disorder, the in vitro contracture test (IVCT) following the European-MH-Group is considered to be the "Gold Standard" for phenotypical determination of predisposed patients. On the other hand mutations in the skeletal muscle ryanodine receptor gene (RYR1) are tightly linked with MH susceptibility. After detecting a C1840T-mutation (Arg614Cys) in the RYR1 gene in one individual of a large MH family, we searched far this mutation in the remaining family members and determined the concordance with IVCT. Methods: According to the European standard protocol for MH, 43 individuals of a large MH pedigree were assigned the status of MH susceptible (MHS), - negative (MHN) or - equivocal (MHE). The genetic investigation of 44 family members for the Arg614Cys-mutation was carried out by restriction fragment analysis:Genomic DNA was prepared from EDTA whole blood followed by amplification of a 918 bp RYR1 gene fragment by polymerase chain reaction. In presence of the Arg614Cys-mutation digestion with the restriction endonuclease RsaI would result in different DNA fragments of the amplified sequence than in absence of mutation. Results: According to the response to IVCT, 25 individuals phenotypically revealed MHS, 7 MHE and 11 MHN status. Out of the 44 family members screened genetically for the Arg614Cys-mutation, the mutation was detected in 23 individuals. Out of them 19 were MHS and one was MHEc. The mutation was absent in 9 predisposed individuals, but six of them were MHE and three MHS. The mutation was also present in three individuals who had no MH screening (IVCT) before. For these last mentioned individuals the diagnosis MHS was deduced from genetic results. Conclusion: Based on results of IVCT the identification of a MH associated mutation in a MH-family can make and support a correct MH diagnosis and can resolve MHE findings.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [1] Reproducibility of in vitro contracture test results in patients tested for malignant hyperthermia susceptibility
    Islander, G
    Örding, H
    Bendixen, D
    Twetman, ER
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2002, 46 (09) : 1144 - 1149
  • [2] An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia
    Hopkins, PM
    Ellis, FR
    Halsall, PJ
    Stewart, AD
    [J]. ANESTHESIA AND ANALGESIA, 1997, 84 (03): : 648 - 656
  • [3] In-vitro-Kontrakturtest und Gentypisierung in der Maligne Hyperthermie-Diagnostik Ein Beispiel für die sinnvolle Ergänzung beider MethodenIn vitro contracture test and gene typing in diagnosing malignant hyperthermia
    H. Rüffert
    D. Olthoff
    C. Deutrich
    B. Thamm
    U. Froster
    [J]. Der Anaesthesist, 2000, 49 (2) : 113 - 120
  • [4] Screening of the ryanodine receptor gene in 105 malignant hyperthermia families:: novel mutations and concordance with the in vitro contracture test
    Brandt, A
    Schleithoff, L
    Jurkat-Rott, K
    Klingler, W
    Baur, C
    Lehmann-Horn, F
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (11) : 2055 - 2062
  • [5] Malignant hyperthermia (MH): Positivity of the in vitro contracture test (ICVT) and associated neuromuscular alterations
    Tsanaclis, AMC
    Timo-Iaria, C
    Castro, I
    Silva, HCA
    [J]. BRAIN PATHOLOGY, 2000, 10 (04) : 537 - 537
  • [6] Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility
    Ording, H
    Islander, G
    Bendixen, D
    Ranklev-Twetman, E
    [J]. ANESTHESIA AND ANALGESIA, 2000, 91 (02): : 452 - 457
  • [7] High-purity ryanodine contracture test for in vitro diagnosis of malignant hyperthermia susceptibility
    Fricker, R
    Musat, J
    Sipos, E
    Gilly, H
    Kress, HG
    [J]. ANESTHESIOLOGY, 1996, 85 (3A) : A977 - A977
  • [8] THE DIAGNOSIS OF MALIGNANT HYPERTHERMIA SUSCEPTIBILITY .1. SIGNIFICANCE OF THE IN-VITRO CONTRACTURE TEST
    MORTIER, W
    BREUCKING, E
    [J]. ANAESTHESIST, 1993, 42 (10): : 675 - 683
  • [9] Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study
    de Mello, Jean Marcel
    Andrade, Pamela Vieira
    Santos, Joilson Moura
    Oliveira, Acary Souza Bulle
    Vainzof, Mariz
    do Amaral, Luiz Gomes
    da Silva, Helga Cristina Almeida
    [J]. BRAZILIAN JOURNAL OF ANESTHESIOLOGY, 2023, 73 (02): : 145 - 152
  • [10] MALIGNANT HYPERTHERMIA SUSCEPTIBILITY REVEALED BY THE INVITRO CONTRACTURE TEST
    KLEIN, W
    SPIESSKIEFER, C
    KUTHER, G
    PONGRATZ, D
    LEHMANNHORN, F
    [J]. ANAESTHESIST, 1987, 36 (12): : 685 - 691